What's Happening?
The U.S. Department of Transportation (DOT), through its Office of the Secretary, has issued a notification in the Federal Register seeking public comments on a petition for rulemaking concerning invalid specimen determinations under 49 CFR Part 40. The petition,
referred to as the Darcy Kern Petition, was published on October 1, 2026, and requests amendments to current regulations regarding drug testing. Specifically, it proposes adding structured medical verification standards for employees who assert a plausible medical explanation for abnormal specimen validity findings, such as unusual pH values. Currently, certain invalid results lead to test cancellation and mandatory directly observed recollection without a formal opportunity to document a medical explanation. The petition suggests five changes, including a defined 72-hour window for submitting medical documentation, written Medical Review Officer (MRO) determinations, defined evaluation standards for abnormal urinary chemistry, consideration of specialist consultation for diagnosed voiding disorders, and documented review of medically supported functional voiding disorders before an MRO verifies a refusal to test. The DOT is accepting comments, data, and information on this petition until November 2, 2026.
Why It's Important?
This petition holds significant importance for employees subject to DOT drug testing, particularly those in safety-sensitive transportation roles, and for employers and Medical Review Officers (MROs) responsible for administering these tests. If adopted, the proposed amendments could introduce a more structured and potentially fairer process for individuals whose drug test specimens are deemed invalid due to medical reasons. This could reduce instances where employees face severe consequences, such as job loss or commercial driver's license disqualification, without a proper medical review. For employers, it might necessitate adjustments to their drug testing protocols and MRO interactions, potentially increasing administrative steps but also enhancing the fairness and defensibility of their testing programs. The current system, which can lead to mandatory observed collections based on certain invalid results, has been criticized for not adequately accounting for legitimate medical conditions. The proposed changes aim to balance anti-adulteration safeguards with employee rights, potentially impacting labor relations and legal challenges related to drug testing in the transportation sector.
What's Next?
The U.S. Department of Transportation will review all comments and information received by the November 2, 2026 deadline to determine whether to grant the petition for rulemaking. It is crucial to note that this notification is not a proposed rule, and the current Part 40 requirements for invalid results and observed collection procedures remain in effect unless and until Part 40 is formally amended. If the DOT decides to grant the petition, it would then initiate rulemaking proceedings to evaluate and potentially adopt the proposed amendments. This process would involve further public input and a detailed regulatory analysis before any changes are finalized and implemented. Stakeholders, including employees, employers, MROs, and industry associations, will be closely watching the DOT's decision, as it could lead to significant modifications in how drug test invalid specimens are handled across various transportation industries.
Beyond the Headlines
The petition's focus on structured medical verification for abnormal specimen validity findings highlights a broader tension between maintaining stringent drug testing standards for public safety and protecting individual medical privacy and rights. The current regulations, which can lead to immediate consequences like observed collections, are designed to prevent tampering and ensure the integrity of drug tests. However, they may inadvertently penalize individuals with legitimate medical conditions that affect specimen parameters. The proposed changes, by introducing a formal medical review process, could set a precedent for how regulatory bodies balance these competing interests. This development could also influence future discussions on drug testing policies in other sectors, potentially leading to calls for similar medical verification standards. The emphasis on specialist consultation for specific medical conditions underscores a move towards more nuanced and medically informed decision-making in drug testing, reflecting evolving understandings of human physiology and medical ethics.
